PARKINSONS DISEASE THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Parkinson's disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms. Levodopa, Dopamine agonists, MAO-B inhibitors, and Anticholinergics are some of the medications used for the treatment of Parkinson’s disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson’s disease. It is useful in controlling the symptoms such as slow movements and stiff & rigid body parts. Medication allows the majority of patients to retain a high quality of life and surgery can help some people improve their symptoms. Parkinson's disease patients also observe decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.

Market Dynamics

Market players are focusing on new product launches, which is expected to propel the Parkinson’s disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc. a pharmaceutical company announced that it received the U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) Sublingual Film for the acute, intermittent treatment for OFF episodes (i.e. re-emergence or worsening of PD symptoms) in patients with Parkinson’s disease. KYNMOBI is available in different strengths such as 10mg, 15mg, 20mg, and 25mg.

 Key features of the study:

• This report provides an in-depth analysis of the global Parkinson’s disease therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Parkinson’s disease therapeutic market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Parkinson’s disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global Parkinson’s disease therapeutic market

Detailed Segmentation:

• Global Parkinson’s Disease Therapeutic Market, By Drug Class
  • Levodopa
  • Dopamine agonists
  • MAO-B inhibitors
  • Anticholinergics
  • Others
• Global Parkinson’s Disease Therapeutic Market, By Route of Administration
  • Oral
  • Injectable
  • Nasal
  • Transdermal
  • Others
• Global Parkinson’s Disease Therapeutic Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Parkinson’s Disease Therapeutic Market, By Region:
  • North America
    • By Drug Class
      • Levodopa
        • Dopamine agonists
        • MAO-B inhibitors
        • Anticholinergics
        • Others
    • By Route of Administration
      • Oral
      • Injectable
      • Nasal
      • Transdermal
      • Others
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By  Drug Class
      • Levodopa
        • Dopamine agonists
        • MAO-B inhibitors
        • Anticholinergics
        • Others
    • By Route of Administration
      • Oral
      • Injectable
      • Nasal
      • Transdermal
      • Others
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Drug Class
      • Levodopa
        • Dopamine agonists
        • MAO-B inhibitors
        • Anticholinergics
        • Others
    • By Route of Administration
      • Oral
      • Injectable
      • Nasal
      • Transdermal
      • Others
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Drug Class
      • Levodopa
        • Dopamine agonists
        • MAO-B inhibitors
        • Anticholinergics
        • Others
    • By Route of Administration
      • Oral
      • Injectable
      • Nasal
      • Transdermal
      • Others
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Drug Class
      • Levodopa
        • Dopamine agonists
        • MAO-B inhibitors
        • Anticholinergics
        • Others
    • By Route of Administration
      • Oral
      • Injectable
      • Nasal
      • Transdermal
      • Others
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Drug Class
      • Levodopa
        • Dopamine agonists
        • MAO-B inhibitors
        • Anticholinergics
        • Others
    • By Route of Administration
      • Oral
      • Injectable
      • Nasal
      • Transdermal
      • Others
    • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Teva Pharmaceutical Industries Ltd.*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Novartis AG
  • GlaxoSmithKline Plc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Zydus Cadila
  • Reddy’s Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Boehringer Ingelheim International GmbH

 “*” marked represents similar segmentation in other categories in the respective section.